Transcription of Early Treatment of COVID-19 with Repurposed Therapies: The ...
{{id}} {{{paragraph}}}
Clinical trialsEarly Treatment of COVID-19 with Repurposed Therapies: The TOGETHER Adaptive Platform TrialBuilding Platform Trial Infrastructure for Infectious trialsCo-Principal InvestigatorsDr. Edward MillsProfessorHealth Research Methods, Evidence, and ImpactMcMaster University Dr. GilmarReisAssociate ProfessorDivision of MedicinePontificia UniversidadeCat licade Minas GeraisClinical trialsSenior InvestigatorsDr. Craig RaynerAssociate ProfessorMonash UniversityPresident, Integrated Drug DevelopmentCertara Angela ReiersenAssociate ProfessorDepartment of Psychiatry, Washington University in St. LouisDr. Eric LenzeProfessorDepartment of Psychiatry, Washington University in St. LouisDr. LehanaThabaneProfessorHealth Research Methods, Evidence and Impact, McMaster UniversityPresident-elect, Society for Clinical Trials (SCT)Dr.
+ Calculated in a Bayesian framework Patients with at least 1 day of treatment Arm Number of patients Number of event Relative risk+ [95% CrI] Fluvoxamine 691 63 0.65[0.48;0.87] Placebo 695 97 Reference
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}